<DOC>
	<DOCNO>NCT02856568</DOCNO>
	<brief_summary>This phase Ib trial study side effect best dose ricolinostat give together gemcitabine hydrochloride cisplatin treat patient cholangiocarcinoma remove surgery spread place body . Ricolinostat may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , gemcitabine hydrochloride cisplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving ricolinostat together gemcitabine hydrochloride cisplatin may work well treat patient cholangiocarcinoma remove surgery spread place .</brief_summary>
	<brief_title>Ricolinostat , Gemcitabine Hydrochloride , Cisplatin Treating Patients With Unresectable Metastatic Cholangiocarcinoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) dose 240 mg/day , whichever low , ricolinostat ( ACY-1215 ) combination gemcitabine cisplatin patient unresectable metastatic cholangiocarcinoma . ( Cohort I ) SECONDARY OBJECTIVES : I . Characterize safety profile ACY-1215 combination gemcitabine cisplatin patient unresectable metastatic cholangiocarcinoma . ( Both cohort ) II . Determine single- multiple-dose pharmacokinetic ( PK ) ACY-1215 combination gemcitabine cisplatin patient unresectable metastatic cholangiocarcinoma . ( Both cohort ) III . To evaluate tumor response treatment ACY-1215 combination gemcitabine cisplatin ( per Response Evaluation Criteria Solid Tumors [ RECIST ] 1.1 criterion ) . ( Both cohort ) IV . To assess progression-free overall survival patient treat ACY-1215 combination gemcitabine cisplatin . ( Both cohort ) TERTIARY OBJECTIVES : I . Both blood tissue sample obtain baseline post-treatment cycle 2 future biomarker development , analysis , potential blood base molecular/genomic profiling . ( Both cohort ) II . Studies Tissue pre-cycle 1 post-cycle 2 therapy include : phospho extracellular signal-regulated kinase ( ERK ) 1/2 ; hedgehog-signaling pathway ( Gli transcription factor ) ; BIM ; histone acetylation ; acetylation alpha ( ) -tubulin ; histone deacetylase ( HDAC ) 6 level ; autophagy marker heat shock protein ( HSP ) 90/70 ; hypoxia-inducible factor 1 ( HIF1 ) alpha ; beclin ; microtubule-associated protein 1A/1B light chain 3 ( LC3 ) ; Ras homolog gene family member B ( RhoB ) . OUTLINE : This dose-escalation study ricolinostat . Patients receive cisplatin intravenously ( IV ) follow gemcitabine hydrochloride IV day 1 8 , ricolinostat orally ( PO ) day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Klatskin Tumor</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Histological cytologic confirmation unresectable metastatic cholangiocarcinoma ( intrahepatic , hilar , extrahepatic bile duct ) Measurable disease Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 Absolute neutrophil count ( ANC ) &gt; = 1200/mm^3 Platelet count &gt; = 100,000/mm^3 Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) , If patient know Gilbert 's syndrome , direct bilirubin &lt; 2.0 x ULN Aspartate transaminase ( AST ) = &lt; 5 x ULN Alkaline phosphatase = &lt; 5 x ULN Creatinine = &lt; 1.5 x ULN Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Ability complete patient medication diary assistance Provide inform write consent Willingness return enrol institution followup ( active monitoring phase study ) Willingness provide tissue blood sample correlative research purpose Life expectancy &gt; = 3 month Prior embolization , chemoembolization , radiofrequency ablation permit &gt; = 4 week registration evidence new tumor growth present Any follow Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Immunocompromised patient patient know human immunodeficiency virus ( HIV ) positive currently receive antiretroviral therapy ; NOTE : patient know HIV positive , without clinical evidence immunocompromised state , eligible trial Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Central nervous system ( CNS ) metastasis ; NOTE : history brain metastasis locally treatable lesion ( i.e. , lesion treatable surgery radiosurgery ) ; patient locally treatable disease may consider study complete treatment without evidence CNS progression &gt; 4 week completion treatment ; patient history brain CNS metastases amenable local therapy eligible Prior biologic immunologic therapy = &lt; 4 week prior study entry Prior systemic chemotherapy cholangiocarcinoma gallbladder carcinoma ; NOTE : adjuvant chemotherapy allow complete &gt; 6 month prior start registration Prior radiation cholangiocarcinoma gallbladder carcinoma ; NOTE : adjuvant radiation therapy allow complete &gt; 6 month prior start registration Receiving investigational agent would consider treatment primary neoplasm Other active malignancy = &lt; 5 year prior registration ; EXCEPTIONS : nonmelanotic skin cancer carcinomainsitu cervix breast , prostatic intraepithelial neoplasm ; NOTE : history prior malignancy , patient must receive specific treatment ( hormonal therapy ) cancer History myocardial infarction = &lt; 6 month registration , congestive heart failure require use ongoing maintenance therapy life threaten ventricular arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>